International Journal of Clinical Pharmacy

, Volume 35, Issue 2, pp 176–180 | Cite as

Utilization of fluconazole in an intensive care unit at a university hospital in Brazil

  • Tânia Pereira SalciEmail author
  • Marina Gimenes
  • Carlos Aparecido dos Santos
  • Terezinha Inez Estivalet Svidzinski
  • Silvana Martins Caparroz-Assef
Short Research Report


Background Fungi have been developing resistance and merit greater attention because these microorganisms are among the major causes of hospital infection. Objective The aim of the present study was to characterize the pattern of fluconazole use in an adult intensive care unit. Setting The setting was an intensive care unit at a university hospital in Brazil. Method An observational retrospective study was performed between 2007 and 2010. The use of antifungal drugs was calculated as the defined daily dose per 1,000 patient-days. The pattern of fluconazole use was determined by analyzing patient charts. Results Fluconazole accounted an average of 66.6 % of the antifungal agents prescribed. All of the patients exhibited important risk factors for the development of fungal infection. Treatment was empirical in 45.2 % of the cases and therapeutic in 54.8 % of the cases. The dose interval was inadequate in 51.1 % of the treatments. Fluconazole at doses ≥400 mg/day was related to a greater likelihood of survival. C. albicans was the most prevalent species (31.3 %). Urine was the biological material with the greatest number of positive mycological exams (71.9 %). Conclusion This study found a high utilization of fluconazole and, in most cases, its administration at intervals that were different from the recommended intervals.


Brazil Cross-infection Drug utilization Fluconazole Intensive care unit Pharmacoepidemiology 



The authors are grateful to the Brazilian fostering agency CAPES for financial support.

Conflicts of interest

The authors declare no conflicts of interest.


  1. 1.
    Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Yap HY, Kwok KM, Gomersall CD, Fung SC, Lam TC, Leung PN, et al. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J. 2009;15(4):255–61.PubMedGoogle Scholar
  3. 3.
    Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55(6):418–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Natsch S, Steeghs MH, Hekster YA, Meis JF, van der Meer JW, Kullberg BJ. Use of fluconazole in daily practice: still room for improvement. J Antimicrob Chemother. 2001;48(2):303–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med. 2009;37(5):1580–93.PubMedCrossRefGoogle Scholar
  6. 6.
    De Bellis P, Bonfiglio M, Gerbi G, Bacigalupo P, Buscaglia G, Guido P, et al. High-dose fluconazole therapy in intensive care unit. Minerva Anestesiol. 2003;69(3):145–52.PubMedGoogle Scholar
  7. 7.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.PubMedCrossRefGoogle Scholar
  9. 9.
    Smith CJ. Analysing censored data using Kaplan-Meier methods; survival analysis. Phlebology. 2011;26(4):173–4.PubMedCrossRefGoogle Scholar
  10. 10.
    World Health Organization (WHO). Medicines: rational use of medicines. (accessed 11 July 2012.).

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Tânia Pereira Salci
    • 1
    Email author
  • Marina Gimenes
    • 1
  • Carlos Aparecido dos Santos
    • 2
  • Terezinha Inez Estivalet Svidzinski
    • 3
  • Silvana Martins Caparroz-Assef
    • 4
  1. 1.Master’s Program in Biosciences Applied to PharmacyUniversity of MaringáMaringáBrazil
  2. 2.Department of StatisticsUniversity of MaringáMaringáBrazil
  3. 3.Department of Clinical Analysis and BiomedicineUniversity of MaringáMaringáBrazil
  4. 4.Department of Pharmacology and TherapeuticsUniversity of MaringáMaringáBrazil

Personalised recommendations